Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
China flag China · Delayed Price · Currency is CNY
2.020
-0.010 (-0.49%)
Sep 26, 2025, 3:00 PM CST

Kangmei Pharmaceutical Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
5,2475,1514,8274,1614,0545,267
Other Revenue
45.6538.3547.318.9598.79144.52
5,2925,1894,8744,1804,1535,412
Revenue Growth (YoY)
6.45%6.46%16.60%0.66%-23.27%-52.72%
Cost of Revenue
4,5144,5364,1453,7494,06129,046
Gross Profit
778.35653.37728.86431.1491.52-23,634
Selling, General & Admin
1,002959.781,0541,0371,2832,021
Research & Development
46.5851.4645.6225.459.2711.36
Other Operating Expenses
29.8430.76-311.78195.22653.49122.99
Operating Expenses
1,1411,067549.271,4713,1383,158
Operating Income
-362.71-413.53179.59-1,040-3,046-26,793
Interest Expense
-18.43-21.39-56.15-78.9-1,022-2,164
Interest & Investment Income
30.3776.4175.1840.77194.062.17
Currency Exchange Gain (Loss)
-----0.02-0.27
Other Non Operating Income (Expenses)
45.2222.74-34.04-16.04-1,041-137.84
EBT Excluding Unusual Items
-305.55-335.77164.57-1,095-4,915-29,093
Impairment of Goodwill
------44.29
Gain (Loss) on Sale of Investments
0.01-0-0.03---4.59
Gain (Loss) on Sale of Assets
11.3939.4719.610.9864.01-45.24
Asset Writedown
-31.81-31.47-99.69-307.46-2,634-1,424
Legal Settlements
-8.87-8.66-12.12-331.49-1,576-516.22
Other Unusual Items
373.19371.0738.03-931.5817,21793.85
Pretax Income
38.3634.65110.37-2,6648,155-31,033
Income Tax Expense
26.0822.576.829.75235.3962.55
Earnings From Continuing Operations
12.2812.08103.57-2,6947,920-31,096
Minority Interest in Earnings
-2.56-3.51-1.055.64-211.19
Net Income
9.718.57102.52-2,6887,918-31,085
Net Income to Common
9.718.57102.52-2,6887,918-31,085
Net Income Growth
-96.02%-91.64%----
Shares Outstanding (Basic)
14,86014,28910,25214,14813,89113,815
Shares Outstanding (Diluted)
14,86014,28910,25214,14813,89113,815
Shares Change (YoY)
33.39%39.38%-27.54%1.85%0.55%179.83%
EPS (Basic)
0.000.000.01-0.190.57-2.25
EPS (Diluted)
0.000.000.01-0.190.57-2.25
EPS Growth
-97.02%-94.00%----
Free Cash Flow
-251.57-489.34-417.27-798.0842.58729.67
Free Cash Flow Per Share
-0.02-0.03-0.04-0.060.000.05
Gross Margin
14.71%12.59%14.95%10.31%2.20%-
Operating Margin
-6.85%-7.97%3.69%-24.89%-73.37%-495.06%
Profit Margin
0.18%0.17%2.10%-64.31%190.68%-574.37%
Free Cash Flow Margin
-4.75%-9.43%-8.56%-19.09%1.03%13.48%
EBITDA
-87.58-131.8470.91-730.42-2,493-26,148
EBITDA Margin
-1.65%-2.54%9.66%-17.47%-60.04%-
D&A For EBITDA
275.13281.73291.32309.93553.19644.83
EBIT
-362.71-413.53179.59-1,040-3,046-26,793
EBIT Margin
-6.85%-7.97%3.68%-24.89%-73.37%-
Effective Tax Rate
67.99%65.13%6.16%-2.89%-
Revenue as Reported
5,2925,1894,8744,1804,1535,412
Advertising Expenses
-55.26193.19114.0699.5259.46
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.